Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pheniprazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 8/20 | 0.63 |
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.63 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.56 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.56 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.56 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pheniprazine SCHEMBL7339052 | 1.00 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Pheniprazine SCHEMBL163709 | 0.98 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Pheniprazine SCHEMBL13063297 | 0.98 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Pheniprazine SCHEMBL28842219 | 0.98 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Benz(B)Anthracene SCHEMBL11128871 | 0.87 | SIGMAR1 (0.53) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Pheniprazine SCHEMBL10867258 | 0.87 | NPC1 (0.56) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Levmetamfetamine SCHEMBL9114800 | 0.80 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2SLC6A4MEN1 | |
| Methamphetamine SCHEMBL42100 | 0.80 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2SLC6A4MEN1 | |
| Levmetamfetamine SCHEMBL42099 | 0.80 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2SLC6A4MEN1 | |
| Methamphetamine SCHEMBL9114797 | 0.80 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2SLC6A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 559 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-20200147137-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | WUGEN, Inc. | 2020-05-14 | — | — | US | claimed |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | claimed |
| EP-2506717-B1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | PERKINELMER INC (US) | 2015-03-25 | — | — | EP | claimed |
| US-20130131127-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | CALIPER LIFE SCIENCES, INC. | 2013-05-23 | — | — | US | claimed |
| EP-2506717-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | PerkinElmer, Inc. (US) | 2012-10-10 | — | — | EP | claimed |
| WO-2011069051-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | CALIPER LIFE SCIENCES, INC. (US) | 2011-06-09 | — | — | WO | claimed |
| JP-56142131-A | — | — | None | — | — | JP | disclosed |
| US-12016845-B2 | BAX activators and uses thereof in cancer therapy | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024107477-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY MEDIATED DELIVERY OF ANTIGEN TO B CELL FOLLICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4370734-A1 | LIGAND-FREE PROCESSABLE PEROVSKITE SEMICONDUCTOR INK | The Regents of the University of California (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240140940-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-05-02 | — | — | US | disclosed |
| EP-3849997-B1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | UNIV MUENCHEN TECH (DE) | 2024-05-01 | — | — | EP | disclosed |
| EP-0080045-A2 | Digital data processing method and means for word classification augmented by ending analysis | SYSTEM DEVELOPMENT CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0079450-A2 | Digital data processing method and means for word classification by pattern analysis | SYSTEM DEVELOPMENT CORPORATION (US) | 1983-05-25 | — | — | EP | disclosed |
| WO-1983001316-A1 | CLASSIFICATION BY PATTERN ANALYSIS | SYSTEM DEV CORP (US) | 1983-04-14 | — | — | WO | disclosed |
| WO-1983001329-A1 | RETRIEVING MISSPELLED AND INFLECTED FORMS OF QUERY WORDS FROM A DIGITAL DATA BASE | SYSTEM DEV CORP (US) | 1983-04-14 | — | — | WO | disclosed |
| US-4305563-A | Computer terminal support | PRESSON BOB E | 1981-12-15 | — | — | US | disclosed |
| JP-S56142131-A | MOLDING DEVICE FOR FLAT TOP TYPE CATRON | EESUPATSUKU KK | 1981-11-06 | — | — | JP | disclosed |
| US-4009817-A | Tray for shipment of frozen items | BAMA PIE, INC. (US) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140940-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | MCL1, BCLAF1, BCL2A1 | SIGMAR1 2147/4885SLC18A2 3159/4885SLC6A2 2031/4885 |
| US-20130131127-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | SLC6A3, SLC6A2, DBH | SIGMAR1 667/4885SLC18A2 5/4885SLC6A2 2/4885 |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | HSD17B7, CYP17A1, HSD17B2 | SIGMAR1 1707/4885SLC18A2 40/4885SLC6A2 101/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | SIGMAR1 174/4885SLC18A2 46/4885SLC6A2 44/4885 |
| US-12016845-B2 | BAX activators and uses thereof in cancer therapy | BAX, BAD, BID | SIGMAR1 4178/4885SLC18A2 4752/4885SLC6A2 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.